Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's
The proposed study by Beersheva Mental Health Center aims to explore the efficacy of EEG-NFB as a novel treatment for Mild Cognitive Impairment (MCI) and early Alzheimer's Disease (AD). Given the increasing prevalence of these conditions, the market potential for effective non-pharmacological interventions is significant. The competitive landscape includes traditional pharmacological treatments, which often have limited efficacy and side effects. If successful, EEG-NFB could position itself as a complementary or alternative therapy, appealing to patients seeking non-invasive options. Diligence should focus on the scalability of the technology, regulatory pathways, and potential reimbursement strategies.
Indication: Mild Cognitive Impairment
Modality: medical device
Target: Posterior cingulate cortex (PCC) modulation via EEG-based neurofeedback (EEG-NFB)
Sponsor: Beersheva Mental Health Center
Source URL: ClinicalTrials.gov
Source updated: Dec 13, 2016
Ingested: Jun 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Posterior cingulate cortex (PCC) modulation via EEG-based neurofeedback (EEG-NFB)
View original source fields
Condition raw: Mild Cognitive Impairment, Alzheimer Disease
Condition normalized: Mild Cognitive Impairment, Alzheimer Disease
Modality raw: medical device
Modality normalized: medical device
Target raw: Posterior cingulate cortex (PCC) modulation via EEG-based neurofeedback (EEG-NFB)
Target normalized: Posterior cingulate cortex (PCC) modulation via EEG-based neurofeedback (EEG-NFB)